from the January 2008 issue

Amarin to buy Israeli R&D company

Amarin Corp Plc (AMRN.L) said it agreed to acquire Israel-based privately held research and development company Ester Neurosciences Ltd for an initial consideration of $15 million, in addition to $17 million in contingent payments.

The British drugmaker said in a statement the deal will close shortly and the transaction will allow Amarin to gain access to a unique mRNA platform technology.

Messenger, or mRNA, is a copy of the information carried by a gene on the DNA. The role of mRNA is to transfer the information contained in DNA to the translation machinery.

Reprinted from the Israel High-Tech & Investment Report January 2008

Click HERE to request further information.
Click HERE to go BACK.